/Content/Upload/Product/87-081_fig1_1200_1.png

Artificial Serum (Animal-free)

Product#: FNK-87-082

$1,255.00

Qty:

Availability:

Ships in 1-2 Weeks

Description
Reviews (0)

Artificial Serum (Animal-free)

Cat No: FNK-87-082

Size 20 ml
Store -20°C

Description

Artificial serum is a serum replacement (supplement for serum-free culture) for the research of regenerative medicine. Generally, when doing cell culture using fetal bovine serum (FBS) or human serum, virus and lot check are required. Our artificial serum enables researchers to skip this burdensome step but can get comparable and stable culture result.

Features

Serum replacement
Suitable for human stem cells, adherent or non-adherent human normal cells, and cells lines.
Tested : (Adherent) Fibroblast, Mesenchymal Stem Cells, and Vero or (Non-adherent) PBMC, DAUDI, etc.
Small volume (1-5%) of artificial serum gives comparable cell proliferation ability to other serum.
Two options : Xeno-free or Animal-free

Example Data

Fig.1 Culture result in adherent cells (Fibroblast)
Population doubling level times (PDL) is comparable between human plasma, artificial serum (xeno-free or animal-free), however, higher cell density is observed than human plasma when using our artificial serum, even half concentration was used.

Fig.2 Culture result in non-adherent cells (DAUDI ; Burkitt′s Lymphoma)
Viable cell density is comparable to the data of 10% human plasma was used.

References

Morokawa H, Yagyu S, Hasegawa A, Tanaka M, Saito S, Mochizuki H, Sakamoto K, Shimoi A, Nakazawa Y. Autologous non-human primate model for safety assessment of piggyBac transposon mediated chimeric antigen receptor T cells on granulocyte–macrophage colony stimulating factor receptor. Clin Transl Immunology. 2020 Nov 22;9(11):e1207. PMID: 33251009; PMCID: PMC7680920.
Tomida A, Yagyu S, Nakamura K, Kubo H, Yamashima K, Nakazawa Y, Hosoi H, Iehara T. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Cancer Sci. 2021 Oct;112(10):4026-4036. doi: 10.1111/cas.15074. Epub 2021 Aug 24. PMID: 34382720; PMCID: PMC8486218.
Suematsu M, Yagyu S, Nagao N, Kubota S, Shimizu Y, Tanaka M, Nakazawa Y, Imamura T. PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function. Front Immunol. 2022 Jan 27;13:770132. doi: 10.3389/fimmu.2022.770132. PMID: 35154098; PMCID: PMC8829551.
Kubo H, Yagyu S, Nakamura K, Yamashima K, Tomida A, Kikuchi K, Iehara T, Nakazawa Y, Hosoi H. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol Ther Oncolytics. 2021 Mar 5;20:646-658. doi: 10.1016/j.omto.2021.03.001. PMID: 33816783; PMCID: PMC7985479.
Yagyu S, Mochizuki H, Yamashima K, Kubo H, Saito S, Tanaka M, Sakamoto K, Shimoi A, Nakazawa Y. A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells. Clin Transl Immunology. 2021 Jun 3;10(6):e1291. doi: 10.1002/cti2.1291. PMID: 34123382; PMCID: PMC8175993.
Nakamura K, Yagyu S, Hirota S, Tomida A, Kondo M, Shigeura T, Hasegawa A, Tanaka M, Nakazawa Y. Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype. Mol Ther Methods Clin Dev. 2021 Mar 23;21:315-324. doi: 10.1016/j.omtm.2021.03.011. PMID: 33898630; PMCID: PMC8047430.
Yamamoto N, Hiramatsu N, Ohkuma M, Hatsusaka N, Takeda S, Nagai N, Miyachi EI, Kondo M, Imaizumi K, Horiguchi M, Kubo E, Sasaki H. Novel Technique for Retinal Nerve Cell Regeneration with Electrophysiological Functions Using Human Iris-Derived iPS Cells. Cells. 2021 Mar 28;10(4):743. doi: 10.3390/cells10040743. PMID: 33800535; PMCID: PMC8067101.